Blood Biomarker Assay Detects Prostate Cancer Early
By LabMedica International staff writers Posted on 12 May 2016 |
Image: A diagram of the NuQ biomarker assay for prostate cancer (Photo courtesy of VolitionRx).
Approximately 14% of men will be diagnosed with prostate cancer at some point during their lifetime and nearly three million men are estimated to be living with prostate cancer in the USA alone.
While more than 80% of all prostate cancers are detected at the local stage, and nearly 100% of men diagnosed and treated at this stage will be disease-free after five years, a small percentage of men experience more rapidly growing, aggressive forms of prostate cancer.
Scientists at the University of Surrey (Guildford, UK) collaborated with a commercial company to carry out a retrospective study on blood samples collected from 537 men, including 266 with prostate cancer and 271 age-matched healthy controls. The most common blood test currently used to detect prostate cancer, the Prostate Specific Antigen (PSA), is reported to detect 53% of prostate cancers at 73% specificity.
The PSA test is commonly used for patient monitoring and other purposes because it is a low-cost, non-invasive test that is easy to use for the patient. The PSA test requires a small amount of blood and uses a common screening platform, known as an enzyme-linked immunosorbent assay (ELISA), that is ubiquitous in healthcare laboratories worldwide. However, sensitivity and specificity of the PSA test remains less than optimal.
The samples in the study were analyzed with a single NuQ biomarker assay (VolitionRx Limited, Namur, Belgium) which detected 71% of early stage I prostate cancer cases and 86% of late stage IV prostate cancer at 93% specificity (7% false negatives). Hardev Pandha, MB ChB, PhD, Director of the Surrey Cancer Research Institute and Professor of Urological Oncology, said, “This NuQ biomarker study has shown very encouraging results in this patient cohort. Further studies are needed but the test may potentially have uses in detecting and monitoring men with prostate cancer.”
Jake Micallef, PhD, MBA, Chief Scientific Officer at VolitionRx, said, “This single NuQ biomarker assay has shown great potential for high accuracy in detecting early stage I prostate cancer. The ability to detect early stage prostate cancer at significantly greater sensitivity than the PSA test with a simple ELISA blood test is a remarkable breakthrough. The accuracy of this single NuQ test may be further improved by use of a combination of NuQ tests in a panel with PSA and this, plus the usefulness of the test for monitoring treatment, will be a focus of future studies by our team. The achievement of high accuracy with a single assay, rather than a panel of assays, is the result of the increasing insight of VolitionRx in predicting and identifying NuQ markers for the detection of specific cancers with high sensitivity and with very few false positives.” The study was presented the American Association for Cancer Research (AACR) Annual Meeting, held April 16-20, 2016, in New Orleans (LA, USA).
Related Links:
VolitionRx
While more than 80% of all prostate cancers are detected at the local stage, and nearly 100% of men diagnosed and treated at this stage will be disease-free after five years, a small percentage of men experience more rapidly growing, aggressive forms of prostate cancer.
Scientists at the University of Surrey (Guildford, UK) collaborated with a commercial company to carry out a retrospective study on blood samples collected from 537 men, including 266 with prostate cancer and 271 age-matched healthy controls. The most common blood test currently used to detect prostate cancer, the Prostate Specific Antigen (PSA), is reported to detect 53% of prostate cancers at 73% specificity.
The PSA test is commonly used for patient monitoring and other purposes because it is a low-cost, non-invasive test that is easy to use for the patient. The PSA test requires a small amount of blood and uses a common screening platform, known as an enzyme-linked immunosorbent assay (ELISA), that is ubiquitous in healthcare laboratories worldwide. However, sensitivity and specificity of the PSA test remains less than optimal.
The samples in the study were analyzed with a single NuQ biomarker assay (VolitionRx Limited, Namur, Belgium) which detected 71% of early stage I prostate cancer cases and 86% of late stage IV prostate cancer at 93% specificity (7% false negatives). Hardev Pandha, MB ChB, PhD, Director of the Surrey Cancer Research Institute and Professor of Urological Oncology, said, “This NuQ biomarker study has shown very encouraging results in this patient cohort. Further studies are needed but the test may potentially have uses in detecting and monitoring men with prostate cancer.”
Jake Micallef, PhD, MBA, Chief Scientific Officer at VolitionRx, said, “This single NuQ biomarker assay has shown great potential for high accuracy in detecting early stage I prostate cancer. The ability to detect early stage prostate cancer at significantly greater sensitivity than the PSA test with a simple ELISA blood test is a remarkable breakthrough. The accuracy of this single NuQ test may be further improved by use of a combination of NuQ tests in a panel with PSA and this, plus the usefulness of the test for monitoring treatment, will be a focus of future studies by our team. The achievement of high accuracy with a single assay, rather than a panel of assays, is the result of the increasing insight of VolitionRx in predicting and identifying NuQ markers for the detection of specific cancers with high sensitivity and with very few false positives.” The study was presented the American Association for Cancer Research (AACR) Annual Meeting, held April 16-20, 2016, in New Orleans (LA, USA).
Related Links:
VolitionRx
Latest Pathology News
- AI Advancements Enable Leap into 3D Pathology
- New Blood Test Device Modeled on Leeches to Help Diagnose Malaria
- Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing
- Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization
- First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests
- AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis
- New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance
- New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis
- Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse
- Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection
- Image-Based AI Shows Promise for Parasite Detection in Digitized Stool Samples
- Deep Learning Powered AI Algorithms Improve Skin Cancer Diagnostic Accuracy
- Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities
- Virtual Skin Biopsy Determines Presence of Cancerous Cells
- AI Detects Viable Tumor Cells for Accurate Bone Cancer Prognoses Post Chemotherapy
- First Ever Technique Identifies Single Cancer Cells in Blood for Targeted Treatments